Compare Stocks: AVTE, BCRX, NUVB, and KOD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$16.74 -1.2%	$20.52	$89.95 ▼ $99.05	$485.21M	0.95	53,591 shs	528,775 shs
BCRX BioCryst Pharmaceuticals	$8.78 +0.2%	$9.39	$6.00 ▼ $11.22	$2.24B	0.57	4.40 million shs	3.44 million shs
KOD Kodiak Sciences	$33.80 +4.3%	$38.89	$10.94 ▼ $47.84	$2.04B	2.18	642,205 shs	1.04 million shs
NUVB Nuvation Bio	$6.12 +0.8%	$6.45	$2.99 ▼ $9.75	$2.13B	1.52	4.37 million shs	4.32 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	-1.18%	-7.92%	-21.56%	-23.81%	+125.61%
BCRX BioCryst Pharmaceuticals	+0.23%	+7.60%	-8.16%	-11.97%	+11.00%
KOD Kodiak Sciences	+4.26%	+2.46%	-11.82%	-6.10%	+125.18%
NUVB Nuvation Bio	+0.67%	+5.63%	-11.55%	-6.13%	+87.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$16.74 -1.2%	$20.52	$89.95 ▼ $99.05	$485.21M	0.95	53,591 shs	528,775 shs
BCRX BioCryst Pharmaceuticals	$8.78 +0.2%	$9.39	$6.00 ▼ $11.22	$2.24B	0.57	4.40 million shs	3.44 million shs
KOD Kodiak Sciences	$33.80 +4.3%	$38.89	$10.94 ▼ $47.84	$2.04B	2.18	642,205 shs	1.04 million shs
NUVB Nuvation Bio	$6.12 +0.8%	$6.45	$2.99 ▼ $9.75	$2.13B	1.52	4.37 million shs	4.32 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	-1.18%	-7.92%	-21.56%	-23.81%	+125.61%
BCRX BioCryst Pharmaceuticals	+0.23%	+7.60%	-8.16%	-11.97%	+11.00%
KOD Kodiak Sciences	+4.26%	+2.46%	-11.82%	-6.10%	+125.18%
NUVB Nuvation Bio	+0.67%	+5.63%	-11.55%	-6.13%	+87.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	2.58	Moderate Buy	$20.40	132.35% Upside
KOD Kodiak Sciences	2.57	Moderate Buy	$53.67	58.78% Upside
NUVB Nuvation Bio	2.69	Moderate Buy	$13.00	112.38% Upside

Current Analyst Ratings Breakdown

Latest AVTE, BCRX, NUVB, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00
9/16/2026	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/16/2026	NUVB Nuvation Bio	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$10.00
9/16/2026	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
9/10/2026	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$13.00 ➝ $11.00
9/8/2026	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
8/27/2026	BCRX BioCryst Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/21/2026	NUVB Nuvation Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/18/2026	NUVB Nuvation Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
8/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00
8/7/2026	NUVB Nuvation Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
BCRX BioCryst Pharmaceuticals	$874.84M	2.56	$1.24 per share	7.08	($0.57) per share	-15.40
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A
NUVB Nuvation Bio	$62.90M	34.17	N/A	N/A	$0.88 per share	6.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
BCRX BioCryst Pharmaceuticals	$263.86M	-$1.50	N/A	12.19	N/A	-40.90%	-86.89%	66.37%	11/2/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)
NUVB Nuvation Bio	-$204.63M	-$0.44	N/A	N/A	N/A	-88.18%	-46.59%	-22.01%	11/2/2026 (Estimated)

Latest AVTE, BCRX, NUVB, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/6/2026	Q2 2026	NUVB Nuvation Bio	-$0.1417	-$0.15	-$0.0083	-$0.18	$27.03 million	$31.69 million
8/5/2026	Q2 2026	BCRX BioCryst Pharmaceuticals	$0.1542	$0.30	+$0.1458	$0.30	$183.28 million	$218.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
BCRX BioCryst Pharmaceuticals	N/A	2.32	2.29
KOD Kodiak Sciences	N/A	2.49	2.49
NUVB Nuvation Bio	0.96	8.37	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
BCRX BioCryst Pharmaceuticals	85.88%
KOD Kodiak Sciences	89.06%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
BCRX BioCryst Pharmaceuticals	3.80%
KOD Kodiak Sciences	44.40%
NUVB Nuvation Bio	30.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
BCRX BioCryst Pharmaceuticals	435	255.54 million	245.83 million	Optionable
KOD Kodiak Sciences	124	62.85 million	34.94 million	Optionable
NUVB Nuvation Bio	305	351.12 million	245.40 million	Optionable

AVTE, BCRX, NUVB, and KOD Headlines

Recent News About These Companies

Wedbush Reiterates "Outperform" Rating for Nuvation Bio (NYSE:NUVB)

September 18, 2026 | americanbankingnews.com

Nuvation Bio (NYSE:NUVB) Earns Market Outperform Rating from Citizens Jmp

September 18, 2026 | americanbankingnews.com

Nuvation Bio Inc.: Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ...

September 17, 2026 | finanznachrichten.de

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive ...

September 17, 2026 | uk.finance.yahoo.com

Nuvation Bio Announces Fda Approval of Supplemental New Drug Application for Ibtrozi (Taletrectinib) with Updated Duration of Response in Tki-Naive Advanced Ros1-Positive Non ...

September 17, 2026 | marketscreener.comM

Nuvation Bio Gets FDA Approval for Updated IBTROZI Label

September 17, 2026 | finance.yahoo.com

Nuvation Bio rises on FDA label update for Ibtrozi

September 17, 2026 | seekingalpha.com

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

September 17, 2026 | prnewswire.com

Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups

September 16, 2026 | finance.yahoo.com

Citizens Jmp Reaffirms Market Outperform Rating for Nuvation Bio (NYSE:NUVB)

September 16, 2026 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Receives Outperform Rating from Wedbush

September 16, 2026 | marketbeat.com

Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World ...

September 15, 2026 | finance.yahoo.com

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

September 15, 2026 | prnewswire.com

NewEdge Advisors LLC Grows Stock Holdings in Nuvation Bio Inc. $NUVB

September 14, 2026 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Trading Down 4.4% - Should You Sell?

September 11, 2026 | marketbeat.com

Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Jim Cramer sends strong 5-word message on surging biotech stock

September 6, 2026 | msn.com

Bank of New York Mellon Corp Invests $3.80 Million in Nuvation Bio Inc. $NUVB

September 6, 2026 | marketbeat.com

Nuvation Bio Inc. (NYSE:NUVB) Receives Average Rating of "Moderate Buy" from Brokerages

September 5, 2026 | marketbeat.com

Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is

September 4, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AVTE, BCRX, NUVB, and KOD Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$16.74 -0.20 (-1.18%)

As of 09/21/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.78 +0.02 (+0.23%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$8.84 +0.06 (+0.63%)

As of 09/22/2026 07:30 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Kodiak Sciences NASDAQ:KOD

$33.80 +1.38 (+4.26%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$33.61 -0.19 (-0.56%)

As of 09/22/2026 07:59 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Nuvation Bio NYSE:NUVB

$6.12 +0.05 (+0.84%)

Closing price 09/22/2026 03:59 PM Eastern

Extended Trading

$6.10 -0.02 (-0.34%)

As of 09/22/2026 07:55 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVTE, BCRX, NUVB, and KOD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVTE, BCRX, NUVB, and KOD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVTE, BCRX, NUVB, and KOD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVTE, BCRX, NUVB, and KOD Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

BioCryst Pharmaceuticals NASDAQ:BCRX

Kodiak Sciences NASDAQ:KOD

Nuvation Bio NYSE:NUVB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVTE, BCRX, NUVB, and KOD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVTE, BCRX, NUVB, and KOD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVTE, BCRX, NUVB, and KOD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVTE, BCRX, NUVB, and KOD Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

BioCryst Pharmaceuticals NASDAQ:BCRX

Kodiak Sciences NASDAQ:KOD

Nuvation Bio NYSE:NUVB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools